Navigation Links
LipoScience Announces Data Presented at the 2013 American Diabetes Association Meeting
Date:6/23/2013

RALEIGH, N.C., June 23, 2013 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the presentation of data at the 73rd Scientific Sessions of the American Diabetes Association (ADA) from June 21-25 in Chicago, Ill.  

During a poster presented Sunday, June 23 at 11:30 a.m. CT, researchers from Duke University Medical Center demonstrate that the novel Lipoprotein Insulin Resistance score (LP-IR), which was developed by LipoScience, is a potentially clinically useful and convenient index of insulin resistance.

"Insulin resistance is accompanied by alterations in lipoprotein metabolism that result in distinct changes in the lipoprotein profile detected by NMR," explained lead investigator William Kraus, M.D, Professor of Cardiology at Duke University and an author of the study. "These data support the LP-IR score, which combines six lipoprotein subclasses and size variables into a single parameter that could serve as a surrogate marker of insulin resistance."

Dr. Kraus and colleagues compared the LP-IR score, with values ranging from 0 (most insulin-sensitive) to 100 (most insulin-resistant), to two standard measures of insulin resistance – one derived from intravenous glucose tolerance tests and the other from the homeostatic model assessment of insulin resistance (HOMA-IR) – in two distinct cohorts of overweight and obese adults. The researchers concluded that the LP-IR score may provide a particularly efficient and effective way to identify insulin-resistant patients who are at increased risk of developing diabetes, so that they might receive the benefit of targeted lifestyle or other interventions.

About LipoScience
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.

LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. These forward-looking statements include statements about the Company's plans for potential future diagnostic tests. Actual results may differ significantly from those projected or suggested in any forward-looking statements.  Further information on potential factors and other risks that could affect the Company's business and operating results is included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time.  These documents are available on the SEC Filings section of the Investor Relations page of the Company's website at http://investor.liposcience.com/. The statements made herein are based on information available to LipoScience as of the date of this press release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE LipoScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... December 2, 2016 On Thursday, ... honored excellence in research, development and innovation in the ... dinner was held in the presence of Sergey Tsyb, ... Russian Federation , Natalia Sanina, First Vice ... Murashko , Head of Roszdravnadzor, National Service of Control ...
(Date:12/2/2016)... Columbia , December 2, 2016 bioLytical Laboratories, ... INSTI HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... "Perfect Harmony comes with ... allowing FCPX editors to create professional looking video in a matter of minutes," ... contains a beautifully designed 3D environment for placing in personal media. Twenty pre-made ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with First 5 ... services to more than 15,900 children 5 years old and younger and treatment services ... over a span of five years to Western University of Health Sciences, UCLA and ...
(Date:12/2/2016)... ... 02, 2016 , ... For over twenty-four years, Doctors on Liens has published a ... find high quality medical care. When the company started in 1997, the directory was ... present day and the now ten-page directory features a vast array of medical specialists ...
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
Breaking Medicine News(10 mins):